| Business Summary | | Transkaryotic
Therapies,
Inc.
is
a
biopharmaceutical
company
developing
protein-
and
cell-based
therapeutics
for
the
treatment
of
a
wide
range
of
human
diseases.
Based
on
three
proprietary
development
platforms:
Gene-Activated
proteins,
Niche
Protein
products,
and
Gene
Therapy,
the
Company
is
building
a
broad
and
renewable
product
pipeline.
Five
products
emerging
from
the
Company's
pipeline
have
been
approved
for
human
clinical
testing,
including
two
late-stage
products,
Dynepo
for
the
treatment
of
anemia,
and
Replagal
for
the
treatment
of
Fabry
disease. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Transkaryotic
Therapies
is
a
biopharmaceutical
company
building
a
product
pipeline
based
on
three
proprietary
development
platforms:
Gene
Activated
proteins,
Niche
Protein
products
and
Gene
Therapy.
For
the
six
months
ended
6/30/01,
revenues
rose
27%
to
$1.9
million.
Net
loss
increased
39%
to
$35.1
million.
Results
reflect
initial
revenues
from
Replagal
enzyme
replacement
therapy,
offset
by
increased
development
and
marketing
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Rodman Moorhead, III, 57 Chairman | -- | Richard Selden, M.D., Ph.D., 42 Pres,
CEO, Director and Chief Scientific Officer | $864K | Daniel Geffken, 44 CFO,
Sr. VP, Sec. | 316K | Michael Astrue, 44 Sr.
VP of Admin., Gen. Counsel | -- | William Pursley, 47 Sr.
VP, Commercial Operations | 351K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|